MX344725B - Metodo entrelazado para tratar cancer o una condicion precancerosa. - Google Patents

Metodo entrelazado para tratar cancer o una condicion precancerosa.

Info

Publication number
MX344725B
MX344725B MX2011012940A MX2011012940A MX344725B MX 344725 B MX344725 B MX 344725B MX 2011012940 A MX2011012940 A MX 2011012940A MX 2011012940 A MX2011012940 A MX 2011012940A MX 344725 B MX344725 B MX 344725B
Authority
MX
Mexico
Prior art keywords
eukaryotic cells
calcium channel
dosage
type calcium
channel inhibitor
Prior art date
Application number
MX2011012940A
Other languages
English (en)
Other versions
MX2011012940A (es
Inventor
J Krouse Andrew
S Gray Lloyd
Macdonald Timothy
Linden Joel
Original Assignee
Tau Therapeutics Llc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tau Therapeutics Llc * filed Critical Tau Therapeutics Llc *
Publication of MX2011012940A publication Critical patent/MX2011012940A/es
Publication of MX344725B publication Critical patent/MX344725B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona un método para tratar una enfermedad o condición en un mamífero, el cual comprende los pasos de: administrar una cantidad terapéuticamente efectiva de un inhibidor de canales de calcio tipo T para retardar o detener de manera efectiva la progresión de células eucarióticas a través de las fases S, G2 y M del ciclo celular para aumentar la proporción de las células eucarióticas en la fase G1, detener la administración del inhibidor de canales de calcio tipo T durante un periodo de tiempo, y administrar una dosificación seleccionada del grupo que consiste de una dosificación de al menos un agente quimioterapéutico, una dosificación de radiación y combinaciones de los mismos, para matar la proporción de células eucarióticas que progresan después de la fase G1 del ciclo celular después de la detención de la administración del inhibidor de canales de calcio tipo T.
MX2011012940A 2009-06-05 2010-06-04 Metodo entrelazado para tratar cancer o una condicion precancerosa. MX344725B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18465809P 2009-06-05 2009-06-05
PCT/US2010/037437 WO2010141842A2 (en) 2009-06-05 2010-06-04 Interlaced method for treating cancer or a precancerous condition

Publications (2)

Publication Number Publication Date
MX2011012940A MX2011012940A (es) 2012-04-20
MX344725B true MX344725B (es) 2017-01-05

Family

ID=43298556

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012940A MX344725B (es) 2009-06-05 2010-06-04 Metodo entrelazado para tratar cancer o una condicion precancerosa.

Country Status (15)

Country Link
US (2) US20120088807A1 (es)
EP (1) EP2437749B8 (es)
JP (2) JP5806210B2 (es)
KR (2) KR20120030112A (es)
CN (2) CN106177963A (es)
AU (1) AU2010256442B2 (es)
CA (1) CA2764499A1 (es)
DK (1) DK2437749T3 (es)
ES (1) ES2661216T3 (es)
IL (2) IL216443A (es)
MX (1) MX344725B (es)
PL (1) PL2437749T3 (es)
SG (3) SG10201402863PA (es)
WO (1) WO2010141842A2 (es)
ZA (1) ZA201108909B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201501496TA (en) 2010-03-01 2015-04-29 Tau Therapeutics Llc Cancer diagnosis and imaging
CN103957923B (zh) * 2011-09-12 2018-05-25 卡维昂公司 用于抑制包括癌干细胞在内的干细胞的增殖、发育或分化的hs.459642单基因簇产物的拮抗剂
US11058624B2 (en) 2014-02-06 2021-07-13 The Procter And Gamble Company Hair care composition comprising cationic polymers and anionic particulates
US11642353B2 (en) 2014-02-06 2023-05-09 The Procter & Gamble Company Hair care composition comprising antidandruff agent and polyquaternium-6
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3585376A4 (en) 2017-02-15 2020-11-25 Cavion, Inc. CALCIUM CHANNELS INHIBITORS
CA3061720A1 (en) 2017-04-26 2018-11-01 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
MX2021003706A (es) 2018-10-03 2021-11-04 Cavion Inc Tratamiento del temblor esencial usando (r)-2-(4-isopropilfenil)-n -(1-(5-(2,2,2- trifluoroetoxi)piridin-2-il)etil)acetamida.
US11964038B2 (en) 2018-10-04 2024-04-23 The Procter & Gamble Company Personal care composition comprising water insoluble solid organic compound
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
US20060000320A1 (en) * 2004-06-30 2006-01-05 Hutton William M Ratchet wrench tool assembly for underground work and process of using
WO2006023881A2 (en) * 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
EP1778619B1 (en) * 2004-08-20 2012-04-04 University Of Virginia Patent Foundation T type calcium channel inhibitors
CN100546579C (zh) * 2006-12-30 2009-10-07 南京工业大学 替莫唑胺聚乳酸纳米微球与制剂及其制备方法
WO2008141189A1 (en) * 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof

Also Published As

Publication number Publication date
ZA201108909B (en) 2013-02-27
JP2016028058A (ja) 2016-02-25
IL216443A0 (en) 2012-02-29
KR20170097237A (ko) 2017-08-25
AU2010256442B2 (en) 2016-07-21
AU2010256442A1 (en) 2012-01-19
JP2012528890A (ja) 2012-11-15
MX2011012940A (es) 2012-04-20
SG10201810806UA (en) 2019-01-30
WO2010141842A3 (en) 2011-04-21
DK2437749T3 (da) 2018-01-29
EP2437749A4 (en) 2013-04-17
KR20120030112A (ko) 2012-03-27
PL2437749T3 (pl) 2018-04-30
JP6159958B2 (ja) 2017-07-12
US20180228822A1 (en) 2018-08-16
EP2437749B8 (en) 2018-02-21
WO2010141842A2 (en) 2010-12-09
CN106177963A (zh) 2016-12-07
IL248482A0 (en) 2016-12-29
SG10201402863PA (en) 2014-10-30
CN102458416A (zh) 2012-05-16
IL216443A (en) 2016-11-30
US20120088807A1 (en) 2012-04-12
ES2661216T3 (es) 2018-03-28
KR101905050B1 (ko) 2018-10-08
JP5806210B2 (ja) 2015-11-10
SG176678A1 (en) 2012-01-30
CA2764499A1 (en) 2010-12-09
IL248482B (en) 2020-08-31
EP2437749B1 (en) 2017-12-20
EP2437749A2 (en) 2012-04-11

Similar Documents

Publication Publication Date Title
MX344725B (es) Metodo entrelazado para tratar cancer o una condicion precancerosa.
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
MX2011008171A (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MY160456A (en) Benzodiazepine bromodomain inhibitor
PA8778101A1 (es) Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
TN2011000416A1 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
MX339002B (es) El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
UA106634C2 (uk) Тверда фармацевтична дозована форма
MY158504A (en) Fatty acid niacin conjugates and their uses
MX360640B (es) Diagnosis e imagenologia de cancer.
EA200802324A1 (ru) Новая форма введения рацекадотрила
MX2015013703A (es) Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas.
CY1121973T1 (el) Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα
UA114699C2 (uk) Комбінована фармацевтична композиція та методи лікування захворювань або станів, пов'язаних з серцево-судинною системою
IN2014DN09437A (es)
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
MX2014003093A (es) Combinacion de pterostilbeno y estatina para el tratamiento de enfermedad metabolica, enfermedad cardiovascular e inflamacion.
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
CL2010001230A1 (es) Metodo para inhibir la melanogenesis que comprende administrar un compuesto esteroidal; composicin farmaceutica; formulacion topica, util en el tratamiento de una enfermedad o condicion que involucra melanogenesis.
UA54591U (ru) Способ лечения варикозной болезни
TN2010000556A1 (en) Pharmaceutical combination

Legal Events

Date Code Title Description
FG Grant or registration